On January 28, 2021, the U.S. Department of Health and Human Services (“HHS”) issued its fifth amendment to the Declaration under the Public Readiness and Emergency Preparedness Act (“PREP Act”) related to COVID-19...more
The World Health Organization (WHO) has determined that the 2019 novel coronavirus is a “global pandemic” and President Trump has declared a national emergency as the impact of the virus on all aspects of daily life continues...more
3/17/2020
/ Biopharmaceutical ,
Biotechnology ,
Centers for Disease Control and Prevention (CDC) ,
China ,
Clinical Trials ,
Coronavirus/COVID-19 ,
Crisis Management ,
Emergency Management Plans ,
Food and Drug Administration (FDA) ,
Good Clinical Practices ,
Infectious Diseases ,
Institutional Review Board (IRB) ,
Italy ,
Life Sciences ,
Medical Devices ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
Netherlands ,
Public Health ,
Reimbursements ,
Research and Development ,
Supply Chain ,
Travel Restrictions ,
Trump Administration ,
UK ,
Vaccinations ,
Vendors ,
World Health Organization
We are excited to bring you issue 76 of our International Products Law Review with insights and updates on all aspects of products law. In this issue, we explore what businesses need to consider when making climate-related...more
1/13/2020
/ Appeals ,
Business Litigation ,
Carbon Emissions ,
Causation ,
Class Action ,
Climate Change ,
Consent ,
Consumer Protection Laws ,
Cookies ,
Court of Justice of the European Union (CJEU) ,
Cybersecurity ,
Disclosure ,
Energy Efficiency ,
EU ,
European Court of Justice (ECJ) ,
Evidence ,
Germany ,
GlaxoSmithKline ,
Legislative Agendas ,
Litigation Funding ,
Litigation Strategies ,
Multidistrict Litigation ,
Opioid ,
Opt-In ,
Pharmaceutical Industry ,
Prescription Drugs ,
Project Management ,
Regulatory Agenda ,
Vaccinations